WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 3, 2019--
Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company
focused on developing and commercializing novel tetracyclines to treat
serious and life-threatening conditions, today announced data from its
preclinical program for TP-2846, the Company’s new pipeline candidate
for acute myeloid leukemia (AML) discovered using Tetraphase’s
proprietary total synthesis platform. The data were presented at the
2019 American Association for Cancer Research (AACR) Annual Meeting,
held March 29-April 3 at the Georgia World Congress Center in Atlanta.
The posters showed results from preclinical in vitro and in
vivo studies demonstrating the activity, potency and unique
mechanism of action (MOA) of TP-2846.
“Preclinical testing has characterized TP-2846 as a novel, potent,
synthetic tetracycline with activity across multiple in vitro and
in vivo cancer models,” said Guy Macdonald, President and Chief
Executive Officer of Tetraphase. “We are very encouraged by these early
data, which suggest that TP-2846 holds the potential to benefit AML
patients regardless of their mutation status. Further, these data show
that because of its unique MOA, TP-2846 may have antileukemic activity
in patients whose cancer has progressed while on different treatment
“TP-2846 has a new MOA that has never before been fully explored
clinically as a viable approach to treating AML,” said Jacques Dumas,
Chief Scientific Officer of Tetraphase. “Our preclinical data
demonstrated high potency across multiple AML cell lines, along with in
vivo tumor responses at well-tolerated doses. These early data are
very encouraging and support the continued preclinical evaluation of
TP-2846 as a potential new antileukemia agent.”
TP-2846 binds to the mitochondrial ribosome, inhibiting protein
translation and inducing apoptosis. Mechanistic assays demonstrated
changes in protein and gene expression – all consistent with disruption
of mitochondrial translation.
TP-2846 showed antiproliferative activity against cultured AML cell
lines in vitro, as well as bone marrow samples derived from AML
patients in ex vivo assays. The data available to date also
suggest that TP-2846’s activity is independent of p53 status. Because of
its novel MOA, TP-2846 maintained antiproliferative activity in cell
lines that are resistant to anthracyclines, cytarabine and venetoclax,
which are currently approved treatments for AML.
In vivo efficacy studies were also performed, comparing TP-2846
to cytarabine and tigecycline, a tetracycline antibacterial, in two AML
mouse xenograft models. In these studies, TP-2846 demonstrated potent,
dose-dependent in vivo efficacy, including greater than 50
percent tumor shrinkage in 19 out of 20 animals treated with TP-2846,
while none in the comparator treatment groups achieved a tumor response
in the same studies. TP-2846 was well tolerated in both models.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using
its proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including bacterial infections
caused by many of the multidrug-resistant bacteria highlighted as urgent
public health threats by the World Health Organization and the Centers
for Disease Control and Prevention. The Company has created more than
3,000 novel tetracycline compounds using its proprietary technology
platform. Tetraphase's lead product, XERAVATM (eravacycline),
is approved for the treatment of complicated intra-abdominal infections
by the U.S. Food and Drug Administration and the European Medicines
Agency. The Company’s pipeline includes TP-271 and TP-6076, which are in
Phase 1 clinical trials, and TP-2846, which is in preclinical testing
for acute myeloid leukemia. Please visit www.tphase.com
for more company information.
Any statements in this press release about our future expectations,
plans and prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, including our key
milestones for 2019 and our anticipated cash runway, and other
statements containing the words "anticipates," "believes," "expects,"
"plans," "will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including whether preclinical data is indicative of
expected clinical data; our cash resources and the expected revenue will
be sufficient to fund our operations in the future; our product
candidates, such as TP2846, will succeed in clinical trials; even if
such clinical trials are successful, whether we may ever achieve
regulatory approval of such product candidates and other clinical,
regulatory and commercial risk factors discussed in the "Risk Factors"
section of our annual report on Form 10-K for the period ended December
31, 2018, filed with the Securities and Exchange Commission on March 15,
2019. In addition, the forward-looking statements included in this press
release represent our views as of April 3, 2019. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
at some point in the future, we specifically disclaim any obligation to
View source version on businesswire.com: https://www.businesswire.com/news/home/20190403005264/en/
Source: Tetraphase Pharmaceuticals, Inc.